이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Beam Therapeutics 관리
관리 기준 확인 4/4
Beam Therapeutics' CEO는 John Evans, Apr2017 에 임명되었습니다 의 임기는 7.17 년입니다. 총 연간 보상은 $ 6.28M, 10.9% 로 구성됩니다. 10.9% 급여 및 89.1% 보너스(회사 주식 및 옵션 포함). 는 $ 23.08M 가치에 해당하는 회사 주식의 1.26% 직접 소유합니다. 23.08M. 경영진과 이사회의 평균 재임 기간은 각각 4.8 년과 4 년입니다.
주요 정보
John Evans
최고 경영자
US$6.3m
총 보상
| CEO 급여 비율 | 10.9% |
| CEO 임기 | 7.3yrs |
| CEO 소유권 | 1.2% |
| 경영진 평균 재임 기간 | 4.9yrs |
| 이사회 평균 재임 기간 | 4.1yrs |
최근 관리 업데이트
Recent updates
Beam Therapeutics: Slow Developmental Progress, But Promising Potential
Jul 01We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn
May 13
Beam Therapeutics: A 'Hold' Amid High Valuation And Uncertain Revenue Prospects
Apr 24Lacklustre Performance Is Driving Beam Therapeutics Inc.'s (NASDAQ:BEAM) Low P/S
Apr 07Beam Therapeutics Inc. (NASDAQ:BEAM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 01Things Look Grim For Beam Therapeutics Inc. (NASDAQ:BEAM) After Today's Downgrade
Feb 29Beam Therapeutics: Cool Tech, But At A Way Inflated Price For Now
Feb 08This Just In: Analysts Are Boosting Their Beam Therapeutics Inc. (NASDAQ:BEAM) Outlook for This Year
Nov 01We're Hopeful That Beam Therapeutics (NASDAQ:BEAM) Will Use Its Cash Wisely
Jul 23Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation
Apr 08Industry Analysts Just Made A Massive Upgrade To Their Beam Therapeutics Inc. (NASDAQ:BEAM) Revenue Forecasts
Nov 08Beam Therapeutics: Now Is Not The Right Time To Own
Sep 15Beam Therapeutics GAAP EPS of -$1.02 misses by $0.05, revenue of $16.65M beats by $7.21M
Aug 09Beam drops 19% as FDA issues clinical hold on blood cancer candidate
Aug 01Revisiting Beam Therapeutics Among Collaborative Catalysts
Jul 10Newsflash: Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Have Been Trimming Their Revenue Forecasts
May 10Beam Therapeutics Worth Watching Because Of Pfizer Interest?
Apr 21Beam Therapeutics: Getting More And More Interesting
Apr 10Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Mar 03Some Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Just Made A Major Cut To Next Year's Estimates
Mar 02Pfizer's Partnership With Beam Therapeutics About Becoming Global Leader In mRNA/Gene Therapy
Jan 19Beam Therapeutics: An Early Company In A Promising Field
Dec 27Beam Therapeutics: Recent Selling Pressure Leaves Behind A CRISPR Buying Opportunity
Dec 20Beam Therapeutics: This Technology Should Be Part Of Every Investor's Portfolio
Oct 01Beam Therapeutics: If You Buy Into The Technology, Buy Into The Stock
Aug 25CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$135m |
| Dec 31 2023 | US$6m | US$685k | -US$133m |
| Sep 30 2023 | n/a | n/a | -US$314m |
| Jun 30 2023 | n/a | n/a | -US$327m |
| Mar 31 2023 | n/a | n/a | -US$316m |
| Dec 31 2022 | US$9m | US$650k | -US$289m |
| Sep 30 2022 | n/a | n/a | -US$315m |
| Jun 30 2022 | n/a | n/a | -US$234m |
| Mar 31 2022 | n/a | n/a | -US$238m |
| Dec 31 2021 | US$14m | US$590k | -US$371m |
| Sep 30 2021 | n/a | n/a | -US$401m |
| Jun 30 2021 | n/a | n/a | -US$408m |
| Mar 31 2021 | n/a | n/a | -US$366m |
| Dec 31 2020 | US$907k | US$529k | -US$196m |
| Sep 30 2020 | n/a | n/a | -US$132m |
| Jun 30 2020 | n/a | n/a | -US$119m |
| Mar 31 2020 | n/a | n/a | -US$106m |
| Dec 31 2019 | US$2m | US$473k | -US$91m |
| Sep 30 2019 | n/a | n/a | -US$86m |
| Jun 30 2019 | n/a | n/a | -US$134m |
| Mar 31 2019 | n/a | n/a | -US$124m |
| Dec 31 2018 | US$4m | US$441k | -US$117m |
보상 대 시장: John 의 총 보상 ($USD 6.28M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 5.67M ).
보상과 수익: John 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
John Evans (46 yo)
7.3yrs
테뉴어
US$6,280,099
보상
Mr. John M. Evans, MBA, served as a Director at Prime Medicine, Inc until September 13, 2022. He serves as Chief Executive Officer and Director at Beam Therapeutics Inc. since January 2018 and served as it...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CEO & Director | 7.3yrs | US$6.28m | 1.19% $ 21.9m | |
| President | 4.5yrs | US$2.79m | 0.13% $ 2.5m | |
| CFO & Treasurer | 4.9yrs | US$2.56m | 0.020% $ 369.2k | |
| Senior VP | 5.3yrs | US$2.28m | 0.054% $ 996.0k | |
| Chief Medical Officer | 3.3yrs | US$2.55m | 0.0017% $ 32.2k | |
| Co-Founder | no data | 데이터 없음 | 데이터 없음 | |
| Co-Founder | no data | 데이터 없음 | 데이터 없음 | |
| Co-Founder | no data | 데이터 없음 | 데이터 없음 | |
| Chief Technology Officer | no data | 데이터 없음 | 데이터 없음 | |
| Chief Scientific Officer | 1.3yrs | 데이터 없음 | 데이터 없음 | |
| Chief Human Resources Officer | 6.9yrs | 데이터 없음 | 데이터 없음 | |
| Chief Manufacturing Officer | no data | 데이터 없음 | 데이터 없음 |
4.9yrs
평균 재임 기간
55yo
평균 연령
경험이 풍부한 관리: BEAM 의 관리팀은 경험 ( 4.8 년 평균 재직 기간)으로 간주됩니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CEO & Director | no data | US$6.28m | 1.19% $ 21.9m | |
| Independent Director | 2.7yrs | US$435.22k | 0% $ 0 | |
| Independent Lead Director | 6.2yrs | US$465.22k | 0.022% $ 398.4k | |
| Independent Director | 4.8yrs | US$450.22k | 0% $ 0 | |
| Independent Director | 3.5yrs | US$447.72k | 0% $ 0 | |
| Independent Director | less than a year | US$772.68k | 데이터 없음 | |
| Independent Director | 5.7yrs | US$442.72k | 0% $ 0 |
4.1yrs
평균 재임 기간
57yo
평균 연령
경험이 풍부한 이사회: BEAM 의 이사회는 경험(평균 재직 기간 4 년)으로 간주됩니다.